WHAT IS CLAIMED IS:

1. A method of treating patients suffering from allergic fungal sinusitis comprising administering intranasally to said patients an effective amount of liquid composition containing a compound of the formula



I

or a pharmaceutically acceptable salt,

and a pharmaceutically acceptable liquid carrier, said composition being intranasally administered to deliver an effective amount of said compound to treat said sinusitis.

2. The method of claim 2 wherein said compound is administered to a patient at a daily dosage of from about 0.03 mg. to 10 mg.

3. The method of claim 2 wherein said dose is from about 0.3 mg. to about 1.8 mg. per day.

4. A method of treating patients suffering from allergic fungal sinusitis comprising administering intranasally to said patents an effective amount of liquid composition containing a compound of the formula.



II

or a pharmaceutically acceptable salt,

and a pharmaceutically acceptable liquid carrier, said composition being administered to deliver an effective amount of said compound intranasally to treat said sinusitis.

5. The method of claim 4 wherein said compound is administered to a patient at a daily dosage of from about 0.03 mg. to 10 mg.

6. The method of claim 5 wherein said dose is from about 0.3 mg. to about 1.8 mg. per day.

7. A method for treating a patient suffering from a disease state which is sinusitis, allergic rhinitis or asthma who is non-responsive to conventional treatments for these disease states comprising administering intranasally to said patients an effective amount of liquid composition containing a compound of the formula



I

or a pharmaceutically acceptable salt,

and a pharmaceutically acceptable liquid carrier, said composition being administered to deliver an effective amount of said inhibitor intranasally to treat said sinusitis.

8. The method of claim 7 wherein said compound is administered to a patient at a daily dosage of from about 0.03 mg. to 10 mg.

9. The method of claim 8 wherein said dose is from about 0.3 mg. to about 1.8 mg. per day.

10. A method for treating a patient suffering from a disease state which is sinusitis, allergic rhinitis or asthma who is non-responsive to conventional treatments for these disease states comprising administering intranasally to said patients an effective amount of liquid composition containing a compound of the formula.



II

or a pharmaceutically acceptable salt,

and a pharmaceutically acceptable liquid carrier, said composition being administered to deliver an effective amount of said inhibitor intranasally to treat said sinusitis.

11. The method of claim 10 wherein said compound is administered to a patient at a daily dosage of from about 0.03 mg. to 10 mg.

12. The method of claim 11 wherein said dose is from about 0.3 mg. to about 1.8 mg. per day.

13. An intranasal spray comprising a liquid composition containing from 0.01 mg. to 10 mg. per ml. of a compound having the formula



I

or a pharmaceutically acceptable salt thereof

and a liquid pharmaceutically acceptable carrier, said composition being in a form suitable to supply said compound intranasally to a patient as a spray in a daily amount of from 0.03 to 10 mg.

14. The spray of claim 13 wherein said carrier is saline.

15. The spray of claim 14 wherein said compound is present in an amount of from 0.3 to 6.0 mg. per ml. of the composition.

16. The spray of claim 13 wherein the composition is present in an amount to supply from 50 to 120 sprays to the patient.

17. An intranasal spray comprising a liquid composition containing from 0.01 mg. 10 mg. per ml. of a compound having the formula



II

and a liquid pharmaceutically acceptable carrier, said composition being in a form suitable to supply through intranasal delivery said compound to a patient as a spray in a daily amount of from 0.03 to 10 mg.

18. The spray of claim 17 wherein said carrier is saline.

19. The spray of claim 18 wherein said compound is present in an amount of from 0.3 to 6 mg. per ml. of the composition.

20. The spray of claim 17 wherein the composition is present in an amount to supply from 50 to 120 sprays to the patient.